Malcolm Stacey of ShareProphets – Feedback and the Big Spanish Connection

But the story is growing fast for one bio science company that I’ve featured quite recently – Feedback (FDBK).

I’ve had one or two scares with the old prostate gland. My father died of prostate cancer and it makes my very nice consultant a bit wary.

So I was interested to learn the very latest RNS from Feedback. The company has formed a 50-50 alliance  with a big Valencia company which is also in the field of diagnosis of serious illnesses. The name of this new set-up is Prostate Checker.

Now I happen to know, having an prostate family history, that cancer of this prostate can be serious or non-serious. This new link up between Feedback technology and the Spanish company should make spotting that difference easier.

I probably don’t need tell you how common prostate cancer is. A couple of years ago, Uncle Tom grew a funny moustache to emphasise the point.

So this technology will probably interest many consultants and hospitals around the globe.

A study of 100 prostate cancer patients by the University College of London has already demonstrated the ability of Feedback technology to differentiate between significant and not-so significant cancers.

The shares are still not at their year’s high of  3.20p, but a few tidy jumps over the last two weeks means we could be getting there.

It doesn’t look to this old punter that the market has woken up to the fact that the technology, known as TexRad, is so useful.

Obviously, if surgeons can identify the stage of cancers more easily, the treatment will be more specific and thus more effective. This is an important medical advance, and worthy I think of my punting money.

As always, though, gang, we must bear in mind that medical pioneers can be vulnerable to competitors and regulations. So not for the more cautious share-shifter.

And now it’s back to the Punter’s Return.